Skip to main content
SpringerLink
Log in

Etanercept in dermatology and off-label use

  • Chapter
TNF-alpha Inhibitors

Part of the book series: Milestones in Drug Therapy ((MDT))

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Gladman DD (1998) Psoriatic arthritis. In: PJ Maddison, DA Isenberg, P Woo, DN Glass (eds): Oxford Textbook of Rheumatology. Oxford University Press, 1071

    Google Scholar 

  2. Bonifati C, Ameglio F (1999) Cytokines in Psoriasis. Int J Dermatol 38: 241–251

    Article  PubMed  CAS  Google Scholar 

  3. Yamauchi PS, Gindi V, Lowe NJ (2004) The treatment of psoriasis and psoriatic arthritis with etanercept: practical considerations on monotherapy, combination therapy, and safety. Dermatol Clin 22: 449–459

    Article  PubMed  CAS  Google Scholar 

  4. Ettehadi P, Greaves WM, Wallach D, Aderka D, Camp RDR (1994) Elevated tumor necrosis factor-α (TNF-α) biological activity in psoriatic skin lesions. Clin Exp Immunol 96: 146–151

    Article  PubMed  CAS  Google Scholar 

  5. Bonifati C, Carducci M, Cordial Fei P, Trento E, Sacerdoti G, Fazio M, Ameglio F (1994) Correlated increases of tumor necrosis factor-a, interleukin-6 and granulocyte monocyte-colony stimulating factor levels in suction blister fluids and sera of psoriatic patients — relationships with disease activity. Clin Exp Derm atoll 19: 383–387

    Article  CAS  Google Scholar 

  6. Mussi A, Bonifati C, Carducci M, D’Agosto G, Pimpinelli F, D’Urso D, D’Auria L, Fazio M, Ameglio F (1997) Serum TNF-α levels correlate with disease severity and are reduced by effective therapy in plaque-type psoriasis. J Biol Regul Homeost Agents 11: 115–118

    PubMed  CAS  Google Scholar 

  7. Partsch G, Steiner G, Leeb BF, Dunky F, Broll H, Smolen JS (1997) Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol 24(3): 518–523

    PubMed  CAS  Google Scholar 

  8. Mease PJ, Goffe BS, Metz J, Vanderstoep A, Finck B, Burge DJ (2000) Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial. Lancet 356: 385–390

    Article  PubMed  CAS  Google Scholar 

  9. Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory B, Salonen D, Rubenstein J, Sharp JT, Tsuji W (2004) Etanercept Treatment of Psoriatic Arthritis. Arthritis Rheum 50(7): 2264–2272

    Article  PubMed  CAS  Google Scholar 

  10. Oh CJ, Das KM, Gottlieb AB (2000) Treatment with anti-tumor necrosis factor a (TNF-α) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions. J Am Acad Dermatol 42: 829–830

    Article  PubMed  CAS  Google Scholar 

  11. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB (2001) Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomized trial. Lancet 357:1842–1847

    Article  PubMed  CAS  Google Scholar 

  12. Gottleib AB, Matheson RT, Lowe N, Krueger GG, Kang S, Goffe BS, Gaspari A, Ling M, Weinstein GD, Nayak A et al (2003) A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 139: 1627–1632

    Article  Google Scholar 

  13. Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, Gottlieb AB (2003) Etanercept as monotherapy in patients with psoriasis. N Engl J Med 349: 2014–2022

    Article  PubMed  CAS  Google Scholar 

  14. Papp KA, Tyring S, Lahfa M, Prinz J, Griffiths CEM, Nakanishi AM, Zitnick R, van de Kerkhof PCM (2005) A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 152: 1304–1312

    Article  PubMed  CAS  Google Scholar 

  15. Enbrel [package insert]. Thousand Oaks (CA). Amgen 2004

    Google Scholar 

  16. Sacher C, Rubbert A, König C, Scharffetter-Kochanek K, Kreig T, Hunzelmann N (2002) Treatment of recalcitrant cicatricial pemphigoid with the tumor necrosis factor a antagonist etanercept. J Am Acad Dermatol 46: 113–115

    Article  PubMed  Google Scholar 

  17. Berookhim B, Fischer HD, Weinberg JM (2004) Treatment of recalcitrant Pemphigus vulgaris with the Tumor Necrosis Factor α Antagonist Etanercept. Cutis 74: 245–247

    PubMed  Google Scholar 

  18. Lin M, Hsu C, Lee JY (2005) Successful treatment of recalcitrant pemphigus vulgaris and pemphigus vegetans with etanercept and carbon dioxide laser. Arch Dermatol 141: 680–682

    Article  PubMed  Google Scholar 

  19. Henter JI, Karlen J, Calming U, Bernstrand C, Andersson U, Fadeel B (2001) Successful treatment of Langerhans’-cell histiocytosis with etanercept. N Engl J Med 345: 1577–1578

    Article  PubMed  CAS  Google Scholar 

  20. Wagner AD, Andresen J, Jendro MC, Hulsemann JL, Zeidler H (2002) Sustained response to tumor necrosis factor a-blocking agents in two patients with SAPHO syndrome. Arthritis Rheum 46(7): 1965–1968

    Article  PubMed  Google Scholar 

  21. Takada K, Aksentijevich I, Mahadevan V, Dean JA, Kelley RI, Kastner DL (2003) Favorable preliminary experience with etanercept in two patients with the hyperimmunoglobulinemia d and periodic fever syndrome. Arthritis Rheum 48(9): 2645–2651

    Article  PubMed  CAS  Google Scholar 

  22. Arbach O, Gross WL, Gause A (2002) Treatment of refractory churg-strauss-syndrome by TNF-α blockade. Immunobiol 206: 496–501

    Article  CAS  Google Scholar 

  23. Cortis E, De Benedetti F, Insalaco A, Cioschi S, Muratori F, D’Urbano LE, Ugazio AG (2004) abnormal production of the tumor necrosis factor inhibitor etanercept and clinical efficacy of tumor in a patient with PAPA syndrome. J Pediatr 145: 851–855

    Article  PubMed  Google Scholar 

  24. Kovach BT, Calamia KT, Walsh JS, Ginsburg WW (2004) Treatment of multicentric reticulohistiocytosis With etanercept. Arch Dermatol 140: 919–921

    Article  PubMed  Google Scholar 

  25. Pasternack FR, Fox LP, Engler DE (2005) silicone granulomas treated with etanercept. Arch Dermatol 141: 13–15

    Article  PubMed  Google Scholar 

  26. Smith KJ, Skelton H (2001) Common variable immunodeficiency treated with a recombinant human IgG, tumour necrosis factor-α receptor fusion protein. Br J Dermatol 144: 597–600

    Article  PubMed  CAS  Google Scholar 

  27. Robinson ND, Guitart J (2003) Recalcitrant, recurrent apthous stomatitis treated with etanercept. Arch Dermatol 139: 1259–1262

    Article  PubMed  Google Scholar 

  28. McGowan JW, Johnson CA, Lynn A (2004) Treatment of pyoderma gangrenosum with etanercept. J Drugs Dermatol 3(4): 441–444

    PubMed  Google Scholar 

  29. Fautrel B, Foltz V, Frances C, Bourgeois P, Rozenberg S (2002) Regression of subacute lupus erythematosus in a patient with rheumatoid arthritis treated with a biologic tumor necrosis factor alpha-blocking agent: comment on the article by Pisetsky and the letter from Aringer et al Arthritis Rheum 46(5): 1408–1409

    Article  PubMed  Google Scholar 

  30. Sfikakis PP (2002) Behçet’s disease: a new target for anti-tumor necrosis factor treatment. Ann Rheum Dis 61(Supl II): ii51–ii53

    PubMed  Google Scholar 

  31. Melikoglu M, Fresko I, Mat C, Ozyazgan Y, Gogus F, Yurdakul S, Hamuryudan V, Yazici H (2005) Short-term trial of etanercept in Behçet’s disease: a double blind, placebo controlled study. J Rheumatol 32: 98–105

    PubMed  CAS  Google Scholar 

  32. Stambe C, Wicks IP (1998) TNF-α and response of treatment-resistant adult-onset Still’s disease to thalidomide. Lancet 352(9127): 544–545

    Article  PubMed  CAS  Google Scholar 

  33. Husni ME, Maier AL, Mease PJ, Overman SS, Fraser P, Gravallese EM, Weinblatt ME (2002) Etanercept in the Treatment of Adult Patients With Still’s Disease. Arthritis Rheum 46(5):1171–1176

    Article  PubMed  CAS  Google Scholar 

  34. Fautrel B, Sibilia J, Mariette X, Combe B (2005) Tumor necrosis factor a blocking agents in refractory adult Still’s disease: an observational study of 20 cases. Ann Rheum Dis 64: 262–266

    Article  PubMed  CAS  Google Scholar 

  35. Tsimberidou AM, Giles FJ, Duvic M, Kurzrock R (2004) Pilot study of etanercept in patients with relapsed cutaneous T-cell lymphomas. J Am Acad Dermatol 51: 200–204

    Article  PubMed  Google Scholar 

  36. Utz JP, Limper AH, Kalra S, Specks U, Scott JP, Vuk-Pavlovic Z, Schroeder DR (2003) Etanercept for the treatment of stage II and stage III progressive pulmonary sarcoidosis. Chest 124(1):177–185

    Article  PubMed  CAS  Google Scholar 

  37. Khanna D, Liebling MR, Louie JS (2003) Etanercept ameliorates sarcoidosis arthritis and skin disease. J Rheumatol 30: 1864–1847

    PubMed  Google Scholar 

  38. Ellman MH, MacDonald PA, Hayes FA (2000) Etanercept as treatment for diffuse scleroderma: a pilot study. Abstract. Arthritis Rheum 43: S392

    Google Scholar 

  39. Penas PF, Fernandez-Herrera J, Garcia-Diez A (2004) Dermatologic treatment of cutaneous graft versus host disease. Am J Clin Dermatol 5(6): 403–416

    Article  PubMed  Google Scholar 

  40. Hattori K, Hirano T, Miyajima H, Yamakawa N, Tateno M, Oshimi K, Kayagaki N, Yagita H, Okumura K (1998) Differential effects of anti-fas ligand and anti-tumor necrosis factor α antibodies on acute graft-versus-host-disease pathologies. Blood 91(11): 4051–4055

    PubMed  CAS  Google Scholar 

  41. Chiang KY, Abhyankar S, Bridges K, Godder K, Henslee-Downey JP (2002) Recombinant human tumor necrosis factor receptor fusion protein as complimentary treatment for chronic graft-versushost disease. Transplantation 73(4): 665–667

    Article  PubMed  CAS  Google Scholar 

  42. Kamarashev J, Lor P, Forster A, Heinzerling L, Burg G, Nestle FO (2002) Generalized pustular psoriasis induced by cyclosporine a withdrawal responding to the tumor necrosis factor alpha inhibitor etanercept. Dermatol 205(2): 213–216

    Article  CAS  Google Scholar 

  43. Weinberg JM (2003) Successful treatment of recalcitrant palmoplantar psoriasis with etanercept. Cutis 72: 396–398

    PubMed  Google Scholar 

  44. www.enbrel.com

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Joan and Sanford Weill Medical College of Cornell University, New York, NY, 10021, USA

    Noah Gratch

  2. St. Luke’s-Roosevelt Hospital, 1090 Amsterdam Avenue Suite 11B, New York, NY, 10025, USA

    Andrew F. Alexis

Authors
  1. Noah Gratch
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrew F. Alexis
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Dermatology, St. Luke’s-Roosevelt Hospital Center, 1090 Amsterdam Avenue, Suite 11D, New York, NY, 10025, USA

    Jeffrey M. Weinberg  & Robin Buchholz  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Birkhäuser Verlag/Switzerland

About this chapter

Cite this chapter

Gratch, N., Alexis, A.F. (2006). Etanercept in dermatology and off-label use. In: Weinberg, J.M., Buchholz, R. (eds) TNF-alpha Inhibitors. Milestones in Drug Therapy. Birkhäuser Basel. https://doi.org/10.1007/3-7643-7438-1_5

Download citation

Publish with us

Policies and ethics

Search

Navigation